A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Trial Profile

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs OCV C02 (Primary)
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
    • 23 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 01 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top